DSP variants are associated with adverse outcomes compared to non-DSP variants and female sex is an adverse prognostic marker in DSP cardiomyopathy, potentially identifying a higher risk sub-group of female patients with DCM9. This evidence concerns the gene DSP and cardiomyopathy.